Introduction: What they say
A study from the Department of Biochemistry and Molecular Biophysics and Department of Microbiology and Immunology, Howard Hughes Medical Institute, Columbia University, New York, NY 10032, USA shows that “Heme Oxygenase 2 Binds Myristate to Regulate Retrovirus Assembly and TLR4 Signaling.” This research paper was published in the 8 February 2017 issue of the journal “Cell Host and microbe” [One of the best research journals in Infectious biology with an I.F of 12.552] by Prof. Goff SP, Zhu Y and others.
What we say:
On the foundation of this interesting finding, Dr L Boominathan PhD, Director-
cum-chief Scientist of GBMD, reports that: Bio-Magnetic based antiviral therapy for HIV-1 infection: Low frequency magnetic fields increases Heme oxygenase 2 (HO-2) expression, blocks N-myristoylation of HIV-1 Gag protein, disrupts HIV-1 budding, and restricts HIV-1 production via up regulation of its target gene
From Significance of the study to Public health relevance:
Given that: (1) more than 37 million people worldwide are living with HIV/AIDS; (2) there is no effective vaccine available for HIV/AIDS; (3) HIV/AIDS tops the list of incurable diseases in humans; (4) the life-long painful drug treatment is required to treat HIV/AIDS and its associated opportunistic infections; (5) the global economic cost spent for HIV treatment is enormous, there is an urgent need to find: (i) a way to restore CD4 T-cells that were lost in HIV/AIDS; (ii) a cheaper alternative to the existing expensive antiviral drugs; (iii) a side-effect-free natural product-based drug; and (iv) a way to cure, not just treat, HIV-1/AIDS.
What is known?
Prof. Goff’s research team has recently shown that HO-2: a) binds the myristate moiety of HIV-1 Gag protein; b) inhibits virus budding; c) binds TRAM, the adaptor protein of Toll-like receptor 4 (TLR4); d) decreases sensitivity to TLR4 ligand lipopolysaccharide; e) negatively regulates TLR4 signalling; and f) inhibits HIV-1 and MLV virions production, suggesting that, by increasing the expression of HO-2 in HIV-1 infected individuals, one may inhibit HIV-1 production; and host inflammatory responses.
From Research findings to Therapeutic opportunity:
This study suggests, for the first time, a biomagnetic-based antiviral therapy against RNA viruses such as HIV-1. Although Magnetic therapy has been shown to control the progression of a number diseases, including cancer, the detailed mechanistic insights is yet to emerge.
Low frequency magnetic fields, by increasing the expression of its target gene, it may increase the expression of Heme oxygenase-2 (HO-2) (Figure 1). Thereby, it may: (1) bind and block the myristate moiety of HIV-1 Gag protein; (2) disrupt HIV-1 budding; (3) restrict HIV-1 infectivity, replication and production; (4) promote clearance of HIV-1 and MLV virions; and (5) strengthen antiviral immunity against RNA viruses.
Thus, microbiologists/virologists may consider encouraging their HIV-1 positive patients to undergo Low frequency magnetic field therapy, at regular intervals, to control HIV-1 infection.
Details of the research findings:
Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed mechanistic information: How Low frequency magnetic fields increases the expression of Heme oxygenase-2 (HO-2)
For payment and purchase details, you may reach us at firstname.lastname@example.org
# Research cooperation
Citation: Boominathan, L., Bio-Magnetic based antiviral therapy for HIV-1 infection: Low frequency magnetic fields increases Heme oxygenase 2 (HO-2) expression, blocks N-myristoylation of HIV-1 Gag protein, disrupts HIV-1 budding, and restricts HIV-1 production via up regulation of its target gene, 19/April/2017, 6.12 pm, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite, drop us a line at email@example.com